Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

CEO

ISIN

US16385C2035

Listings

0 Comments

Share your thoughts

FAQ

What is Chemomab Therapeutics stock price today?▼

The current price of CMMB.BOATS is $2.18 USD — it has increased by +0% in the past 24 hours. Watch Chemomab Therapeutics stock price performance more closely on the chart.

What is Chemomab Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Chemomab Therapeutics stocks are traded under the ticker CMMB.BOATS.

What is Chemomab Therapeutics revenue for the last year?▼

Chemomab Therapeutics revenue for the last year amounts to 0 USD.

What is Chemomab Therapeutics net income for the last year?▼

CMMB.BOATS net income for the last year is -27.89M USD.

When did Chemomab Therapeutics complete a stock split?▼

Chemomab Therapeutics has not had any recent stock splits.